Morning Overview on MSN
Disabling a single protein called NFIL3 kept CAR T-cells fighting tumors longer in a screen of 400 transcription factors
Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to ...
Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...
At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the ...
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their ...
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...
Exton, PA, May 21, 2026 (GLOBE NEWSWIRE) -- Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest that operational and logistical ...
LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments for blood diseases, is pleased to announce the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results